alexa WHO global tuberculosis control report
Microbiology

Microbiology

Clinical Microbiology: Open Access

Author(s): World Health Organization

Abstract Share this page

8he World Health Organization (WHO) has published an annual report on global control of tuberculosis (TB) every year since 1997. The main purpose of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress made in TB care and control at global, regional and country levels. Progress towards global targets set for 2015 is given particular attention. The target included in the Millennium Development Goals (MDGs) is that TB incidence should be falling by 2015. The Stop TB Partnership has set two additional targets, which are to halve rates of prevalence and mortality by 2015 compared with their levels in 1990. Collectively, the WHO’s Stop TB Strategy and the Stop TB Partnership’s Global Plan to Stop TB have set out how the 2015 targets can be achieved. This fifteenth annual report1 contains more up-todate information than any previous report in the series, following earlier data collection and the completion of the production cycle within a calendar year. The estimates of the global burden of disease caused by TB in 2009 are as follows: 9.4 million incident cases (range, 8.9 million–9.9 million), 14 million prevalent cases (range, 12 million–16 million), 1.3 million deaths among HIV-negative people (range, 1.2 million–1.5 million) and 0.38 million deaths among HIV-positive people (range, 0.32 million–0.45 million). Most cases were in the South-East Asia, African and Western Pacific regions (35%, 30% and 20%, respectively). An estimated 11–13% of incident cases were HIV-positive; the African Region accounted for approximately 80% of these cases. There were 5.8 million notified cases of TB in 2009, equivalent to a case detection rate (CDR, defined as the proportion of incident cases that were notified) of 63% (range, 60–67%), up from 61% in 2008. Of the 2.6 million patients with sputum smear-positive pulmonary TB in the 2008 cohort, 86% were successfully treated. New and compelling data from 15 countries show that efforts by national TB programmes (NTPs) to engage all care providers in TB control (termed public-private mix, or PPM) can be a particularly effective way to increase the CDR. In areas where PPM was implemented, nonNTP providers accounted for around one-fifth to onethird of total notifications in 2009. In 2009, 26% of TB patients knew their HIV status (up from 22% in 2008), including 53% of patients in the African Region. A total of 300 000 HIV-positive TB patients were enrolled on co-trimoxazole preventive therapy, and almost 140 000 were enrolled on antiretroviral therapy (75% and 37% respectively of those who tested HIV-positive). To prevent TB, almost 80 000 people living with HIV were provided with isoniazid preventive therapy. This is an increase from previous years, but still represents less than 1% of the estimated number of people living with HIV worldwide. Among TB patients notified in 2009, an estimated 250 000 (range, 230 000–270 000) had multidrugresistant TB (MDR-TB). Of these, slightly more than 30 000 (12%) were diagnosed with MDR-TB and notified. Diagnosis and treatment of MDR-TB need to be rapidly expanded. Funding for TB control continues to increase and will reach almost US$ 5 billion in 2011. There is considerable variation in what countries spend on a per patient basis (

  • To read the full article Visit
  • Open Access
This article was published in WHO and referenced in Clinical Microbiology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords